Benserazide dosing regimen affects the response to L-3,4- dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat

Behavioural Pharmacology

Volumn 23, Issue 2, 2012, Pages 126-133

  Tayarani Binazir, Kayhan A ^a   Jackson, Michael J ^a   Strang, Isobel ^a   Jairaj, Mark ^a   Rose, Sarah ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

6 hydroxydopamine; benserazide; L 3,4 dihydroxyphenylalanine; Parkinson's disease; rat

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; BENSERAZIDE; LEVODOPA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG RESPONSE; ENZYME INHIBITION; MALE; NONHUMAN; PARKINSON DISEASE; PROCESS OPTIMIZATION; RAT; THERAPY DELAY;

ANIMALS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BENSERAZIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; LEVODOPA; MALE; MICROINJECTIONS; MOTOR ACTIVITY; OXIDOPAMINE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 84858706449     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32834f9f82     Document Type: Article

References (36)

1. Arai A, Kannari K, Shen H, Maeda T, Suda T, Matsunaga M (2003). Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats. Brain Res 972:229-234. (Pubitemid 36507096)
2. Bartholini G, Pletscher A (1969). Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine. J Pharm Pharmacol 21: 323-324.
3. Ben V, Blin O, Bruguerolle B (1999). Time-dependent striatal dopamine depletion after injection of 6-hydroxydopamine in the rat: comparison of single bilateral and double bilateral lesions. J Pharm Pharmacol 51:1405-1408. (Pubitemid 30064070)
4. Birkmayer W, Hornykiewicz O (2001). The effect of l-3, 4-dihydroxyphenylalanine ( =DOPA) on akinesia in parkinsonism. 1961. Wien Klin Wochenschr 113:851-854.
5. Boulamery A, Simon N, Vidal J, Bruguerolle B (2010). Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study. Chronobiol Int 27:251-264.
6. Carey RJ (1991). Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance. Brain Res 568:205-214.
7. Carey RJ, Pinheiro-Carrera M, Tomaz C, Huston JP (1994). Early L-dopa treatment initially retards but later enhances dopamine receptor supersensitivity following unilateral dopamine denervation. Brain Res 658: 145-154. (Pubitemid 24291713)
8. Cenci MA, Lundblad M (2006). Post-versus presynaptic plasticity in L-DOPAinduced dyskinesia. J Neurochem 99:381-392. (Pubitemid 44477196)
9. Da PM, Kettler R, Zurcher G, Schaffner R, Haefely WE (1987). Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol 27 (Suppl 1):9-20. (Pubitemid 17152033)
10. Dekundy A, Lundblad M, Danysz W, Cenci MA (2007). Modulation of L-DOPAinduced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179:76-89. (Pubitemid 46441485)
11. del Amo EM, Urtti A, Yliperttula M (2008). Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 35:161-174.
12. Gaytan O, Swann A, Dafny N (1998a). Diurnal differences in rat's motor response to amphetamine. Eur J Pharmacol 345:119-128. (Pubitemid 28212341)
13. Gaytan O, Swann A, Dafny N (1998b). Time-dependent differences in the rat's motor response to amphetamine. Pharmacol Biochem Behav 59:459-467. (Pubitemid 28072743)
14. Gravotta L, Gavrila AM, Hood S, Amir S (2011). Global depletion of dopamine using intracerebroventricular 6-hydroxydopamine injection disrupts normal circadian wheel-running patterns and PERIOD2 expression in the rat forebrain. J Mol Neurosci 45:162-171.
15. Greenacre JK, Coxon A, Petrie A, Reid JL (1976). Comparison of levodopa with carbidopa or benserazide in parkinsonism. Lancet 2:381-384.
16. Hodge JV, Oates JA, Sjoerdsma A (1964). Reduction of the central effects of tryptophan by a decarboxylase inhibitor. Clin Pharmacol Ther 5:149-155.
17. Holtz P, Balzer H, Westermann E, Wezler E (1957). Effect of reserpine, iproniazid & biogenic amines on evipan narcosis. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 231:333-348.
18. Jonkers N, Sarre S, Ebinger G, Michotte Y (2001). Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J Neural Transm 108:559-570. (Pubitemid 32441871)
19. Kuoppamaki M, Poewe W, Leinonen M, Nissinen H (2008). Optimising levodopa therapy in both levodopa/carbidopa-treated and levodopa/benserazidetreated patients. 12th Congress of the European Federation of Neurological Societies.
20. Lane EL, Cheetham SC, Jenner P (2005). Repeated administration of the monoamine reuptake inhibitor BTS 74398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours. Eur J Neurosci 21:179-186. (Pubitemid 40193886)
21. Lane EL, Cheetham SC, Jenner P (2006). Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Exp Neurol 197: 284-290. (Pubitemid 43077136)
22. Lane EL, Cheetham S, Jenner P (2008). Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74398. J Neural Transm 115:423-429.
23. Lindgren HS, Rylander D, Ohlin KE, Lundblad M, Cenci MA (2007). The 'motor complication syndrome' in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res 177:150-159. (Pubitemid 46054185)
24. Monville C, Torres EM, Pekarik V, Lane EL, Dunnett SB (2009). Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model. Brain Res Bull 78:248-253.
25. Ngwuluka N, Pillay V, Du Toit LC, Ndesendo V, Choonara Y, Modi G, Naidoo D (2010). Levodopa delivery systems: advancements in delivery of the gold standard. Expert Opin Drug Deliv 7:203-224.
26. Nutt JG (2008). Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 23 (Suppl 3):S580-S584.
27. Nutt JG, Fellman JH (1984). Pharmacokinetics of levodopa. Clin Neuropharmacol 7:35-49. (Pubitemid 14138567)
28. Nutt JG, Woodward WR (1986). Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36:739-744. (Pubitemid 16056209)
29. Paxinos G, Watson C, Pennisi M, Topple A (1985). Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. J Neurosci Methods 13:139-143. (Pubitemid 15008633)
30. Rose S, Ramsay CN, Jenner P (2007). The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Res 1133:110-114. (Pubitemid 46123239)
31. Schmidt RH, Ingvar M, Lindvall O, Stenevi U, Bjorklund A (1982). Functional activity of substantia nigra grafts reinnervating the striatum: neurotransmitter metabolism and [14C]2-deoxy-D-glucose autoradiography. J Neurochem 38:737-748. (Pubitemid 12120611)
32. Shen H, Kannari K, Yamato H, Arai A, Matsunaga M (2003). Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopaminelesioned rats. Tohoku J Exp Med 199:149-159. (Pubitemid 36519467)
33. Stefanova N, Lundblad M, Tison F, Poewe W, Cenci MA, Wenning GK (2004). Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). Neurobiol Dis 15: 630-639. (Pubitemid 38429978)
34. Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P (2010). The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset. Eur J Pharmacol 635:109-116.
35. Treseder SA, Rose S, Jenner P (2001). The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats. Eur J Neurosci 13:162-170. (Pubitemid 32055875)
36. Ungerstedt U (1968). 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107-110.